THERAPY DOSSIER · th-fea6fd621416

Meglumine cyclic adenylate (MCA)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24970286 ↗2014Reported benefit

Meglumine cyclic adenylate improves neurological function following acute spinal cord injury in rats.

RatSpinal cord injuryContusionSprague-Dawleyn = 48 rats total, 16 per group; 8 per group for biochemistry a…Intraperitoneal2 mg/kg body weight (methylprednisolone comparator 30 mg/kg…First dose 30 min after injury

Model: Acute spinal cord injury by Allen's weight-drop method, 7 g x 3 cm extradural impact at spinal segment T11

Both meglumine cyclic adenylate and methylprednisolone groups showed higher cAMP concentrations and adenylate cyclase 3 activity, lower phosphodiesterase 4D activity at the lesion site and better behavioural scores than saline controls (P<0.05). cAMP was higher with meglumine cyclic adenylate than…

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…